Evaluation of the metastatic colorectal cancer score (mCCS) in predicting outcome for patients with RAS wild type metastatic colorectal cancer (mCRC) treated with first-line (1L) panitumumab (PAN) plus FOLFIRI/FOLFOX: Updated interim results of the non-interventional study VALIDATE

被引：0
|
作者：
Reiser, M. [1 ]
Uhlig, J. [2 ]
Jacobasch, L. [3 ]
Mueller, L. [4 ]
Schuch, A. [5 ]
Serrer, L. [5 ]
de Buhr, R. [6 ]
Siebenbach, H. U. [7 ]
Goehler, T. [8 ]
Schroeder, K. [9 ]
Semsek, D. [10 ]
Koehler, A. [11 ]
Stuebs, P. [12 ]
Potthoff, K. M. [6 ]
Marschner, N. W. [6 ]
机构：
[1] Praxis Internist Onkol & Hamatol, PIOH Koln Zentrum, Cologne, Germany
[2] Praxis Dr Med Jens Uhlig, Naunhof, Germany
[3] Gemeinschaftspraxis Haematol Onkol, Oncol Heamatol Dept, Dresden, Germany
[4] Onkol Untere Ems Leer Papenburg Emden, Leer, Germany
[5] IOMEDICO AG, Clin Operat, Freiburg, Germany
[6] IOMEDICO AG, Med Dept, Freiburg, Germany
[7] IOMEDICO AG, Biostat, Freiburg, Germany
[8] Onkol Gemeinschaftspraxis, Dresden, Germany
[9] MVZ Hamatol & Onkol Mulheim Ruhr, Mulheim, Germany
[10] Praxis Interdisziplinaere Onkol & Haematol, Freiburg, Germany
[11] Onkol Schwerpunktpraxis, Langen, Hessen, Germany
[12] DRK Kliniken Berlin Kopenick, Klinik Allgemein Viszeral & Minimalinvas Chirurg, Berlin, Germany
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1813
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
622P
引用
收藏
页码：S445 / S445
页数：1
相关论文
共 50 条
  • [41] Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI plus bevacizumab
    Budai, Barna
    Komlosi, Viktor
    Adleff, Vilmos
    Pap, Eva
    Reti, Andrea
    Nagy, Tuende
    Kralovanszky, Judit
    Lang, Istvan
    Hitre, Erika
    PHARMACOGENETICS AND GENOMICS, 2012, 22 (01): : 69 - 72
  • [42] A Non-Interventional Multicenter Study of First-Line Bevacizumab in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon
    Temraz, Sally
    Nasr, Fadi
    Kattan, Joseph
    Abigerges, Dany
    Moukadem, Walid
    Farhat, Fadi
    Maatouk, Layal
    Chahine, Georges
    Shamseddine, Ali
    BIOLOGICS-TARGETS & THERAPY, 2022, 16 : 7 - 15
  • [43] Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy
    Yamaguchi, Kensei
    Ando, Masahiko
    Ooki, Akira
    Beier, Frank
    Guenther, Silke
    von Hohnhorst, Philipp
    Van Cutsem, Eric
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : E29 - E37
  • [44] First-line treatment with panitumumab plus FOLFIRI in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer and good performance status: OPALO trial.
    Feliu, Jaime
    Salud, Antonieta
    Losada, Estela Pineda
    Alonso, Vicente
    Cubillo, Antonio
    Soler, Gemma
    Carmona, Alberto
    Casado, Ana Ruiz
    Martinez-Amores, Brenzo
    Morales, Monica Guillot
    Llorca, Cristina
    Lopez, Carmen Castanon
    Gonzalez, Gemma Soler
    Escudero, Pilar
    Declara, Ismael Macias
    Aparicio, Jorge
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer
    Price, Timothy
    Shen, Lin
    Ma, Brigette
    Esser, Regina
    Chen, Wenfeng
    Gibbs, Peter
    Lim, Robert
    Cheng, Ann-Lii
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (04) : 225 - 230
  • [46] Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial
    Kasper, Stefan
    Meiler, Johannes
    Knipp, Heike
    Hohler, Thomas
    Reimer, Peter
    Steinmetz, Tilman
    Berger, Winfried
    Linden, Gabriele
    Reis, Henning
    Markus, Peter
    Paul, Andreas
    Dechene, Alexander
    Schumacher, Brigitte
    Kostbade, Karina
    Virchow, Isabel
    Ting, Saskia
    Worm, Karl
    Schmid, Kurt W.
    Herold, Thomas
    Wiesweg, Marcel
    Schuler, Martin
    Trarbach, Tanja
    CLINICAL COLORECTAL CANCER, 2020, 19 (04) : 236 - +
  • [47] Impact of first-line bevacizumab (BV) on the clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with second-line FOLFIRI plus BV
    Muro, Kei
    Yamanaka, Takeharu
    Suenaga, Mitsukuni
    Nishina, Tomohiro
    Yasul, Hisateru
    Ura, Takashi
    Denda, Tadamichi
    Ikeda, Junichi
    Esakl, Taito
    Nishisaki, Hogara
    Takano, Yoshinao
    Kondo, Ken
    Takeda, Koji
    Takahashi, Yasuo
    Endo, Kazuya
    Sugiyama, Yasuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [48] Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181
    Peeters, M.
    Price, T. J.
    Strickland, A. H.
    Ciuleanu, T. E.
    Scheithauer, W.
    O'Reilly, S.
    Keane, M. M.
    Spigel, D. R.
    Tian, Y.
    Krishnan, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] Impact of primary tumour location (PTL) on outcomes in patients (pts) with metastatic colorectal cancer (mCRC) undergoing first-line panitumumab (Pmab) plus FOLFIRI treatment
    Karthaus, Meinolf
    Van Den Eynde, Marc
    Mineur, Laurent
    Thaler, Josef
    Koukakis, Reija
    Berkhout, Marloes
    Gallego, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [50] Impact of depth of response (DpR) on survival in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line panitumumab+FOLFOX4 vs FOLFOX4
    Siena, S.
    Rivera Herrero, F.
    Douillard, J-Y.
    Taieb, J.
    Koukakis, R.
    Demonty, G.
    Peeters, M.
    ANNALS OF ONCOLOGY, 2016, 27
12345